The distinctive nature of HER2-positive breast cancers.

@article{Burstein2005TheDN,
  title={The distinctive nature of HER2-positive breast cancers.},
  author={H. Burstein},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 16},
  pages={
          1652-4
        }
}
  • H. Burstein
  • Published 2005
  • Medicine
  • The New England journal of medicine
  • The history of HER2 and trastuzumab treatment is a triumphal narrative of translational research. Dr. Harold Burstein writes that like all good stories, this one has a profound lesson: not all breast cancers are the same. 
    373 Citations

    Topics from this paper

    Paper Mentions

    Interventional Clinical Trial
    To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2 single domain antibody (sdAb) (Product Code Name: 99mTc-NM02 and 188Re-NM02) SPECT/CT imaging of HER2… Expand
    ConditionsBreast Cancer
    InterventionDrug
    Interventional Clinical Trial
    RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die… Expand
    ConditionsBreast Cancer
    InterventionBiological, Drug
    Interventional Clinical Trial
    Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front… Expand
    ConditionsMetastatic Breast Cancer
    InterventionDrug
    From tumor size and HER2 status to systems oncology for very early breast cancer treatment
    • 67
    Cytokeratin profiles of male breast cancers
    • 33
    • PDF
    HER2 status in breast cancer--an example of pharmacogenetic testing.
    • 25
    Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
    • 284
    • PDF
    Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction

    References

    SHOWING 1-6 OF 6 REFERENCES
    Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    • 4,487
    • PDF
    Untangling the ErbB signalling network
    • 5,941
    • PDF
    Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    • 4,905
    • PDF
    Molecular portraits of human breast tumours
    • 13,022
    • PDF